1. 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC). (10th December 2020) Authors: Hou, Ming-Mo; Rau, Kun-Ming; Kang, Yoon-Koo; Lee, Jong-Seok; Pan, Hongming; Yuan, Ying; Yu, Cunjing; Zhang, Yun; Ma, Xiaopeng; Wu, Xikun; Li, Xin; Wood, Katie; Yen, Chia-Jui Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. (April 2022) Authors: Lin, Lin; Pan, Hongming; Li, Xingya; Zhao, Chengling; Sun, Jiangtao; Hu, Xingsheng; Zhang, Yiping; Wang, Mengzhao; Ren, Xiubao; Luo, Xiaoyong; Shan, Guoyong; Hui, Ai-Min; Wu, Zhuli; Liu, Huilong; Tian, Ling; Shi, Yuankai Journal: Lung cancer Issue: Volume 166(2022) Page Start: 98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. (December 2019) Authors: Qin, Shukui; Chan, Stephen Lam; Sukeepaisarnjaroen, Wattana; Han, Guohong; Choo, Su Pin; Sriuranpong, Virote; Pan, Hongming; Yau, Thomas; Guo, Yabing; Chen, Minshan; Ren, Zhenggang; Xu, Jianming; Yen, Chia-Jui; Lin, Zhong-Zhe; Manenti, Luigi; Gu, Yi; Sun, Yongjian; Tiedt, Ralph; Hao, Lu; Song, We... Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. (August 2020) Authors: Lu, Shun; Chen, Gongyan; Sun, Yuping; Sun, Sanyuan; Chang, Jianhua; Yao, Yu; Chen, Zhendong; Ye, Feng; Lu, Junguo; Shi, Jianhua; He, Jianxing; Liu, Xiaoqing; Zhang, Yiping; Liu, Zhihua; Fang, Jian; Cheng, Ying; Hu, Chunhong; Mao, Weidong; Hu, Yanping; Gong, Youling Journal: Lung cancer Issue: Volume 146(2020) Page Start: 252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. (17th August 2018) Authors: Li, Jin; Xu, Ruihua; Qin, Shukui; Liu, Tianshu; Pan, Hongming; Xu, Jianming; Bi, Feng; Lim, Robert; Zhang, Suzhan; Ba, Yi; Bai, Yuxian; Fan, Nanfeng; Tsuji, Akihito; Yeh, Kun-Huei; Ma, Brigette; Wei, Vivian; Shi, Dongmei; Magherini, Emmanuelle; Shen, Lin Journal: Future oncology Issue: Volume 14:Number 20(2018) Page Start: 2031 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Analysis of potential genes and pathways associated with the colorectal normal mucosa–adenoma–carcinoma sequence. (16th April 2018) Authors: Wu, Zhuoxuan; Liu, Zhen; Ge, Weiting; Shou, Jiawei; You, Liangkun; Pan, Hongming; Han, Weidong Journal: Cancer medicine Issue: Volume 7:Number 6(2018:Jun.) Page Start: 2555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Antitumour bioactive peptides isolated from marine organisms. (16th October 2017) Authors: Xing, Haibo; Tong, Mengting; Jiang, Nanyu; Zhang, Xiaomin; Hu, Hong; Pan, Hongming; Li, Da Journal: Clinical and experimental pharmacology and physiology Issue: Volume 44:Number 11(2017:Nov.) Page Start: 1077 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (July 2021) Authors: Qin, Shukui; Li, Qiu; Gu, Shanzhi; Chen, Xiaoming; Lin, Lizhu; Wang, Zishu; Xu, Aibing; Chen, Xi; Zhou, Cuncai; Ren, Zhenggang; Yang, Lin; Xu, Li; Bai, Yuxian; Chen, Lei; Li, Jun; Pan, Hongming; Cao, Bangwei; Fang, Weijia; Wu, Wei; Wang, Ge Journal: Lancet gastroenterology and hepatology Issue: Volume 6:Number 7(2021) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bacterial xenophagy and its possible role in cancer: A potential antimicrobial strategy for cancer prevention and treatment. Issue 2 (1st February 2017) Authors: Sui, Xinbing; Liang, Xiao; Chen, Liuxi; Guo, Chunming; Han, Weidong; Pan, Hongming; Li, Xue Journal: Autophagy Issue: Volume 13:Issue 2(2017) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial. Issue 9 (29th June 2021) Authors: Shi, Yuankai; Lei, Kaijian; Jia, Yuming; Ni, Bingqiang; He, Zhiyong; Bi, Minghong; Wang, Xicheng; Shi, Jianhua; Zhou, Ming; Sun, Qian; Wang, Guolei; Chen, Dongji; Shu, Yongqian; Liu, Lianke; Guo, Zhongliang; Liu, Yong; Yang, Junquan; Wang, Ke; Xiao, Ke; Wu, Lin Journal: Cancer communications Issue: Volume 41:Issue 9(2021) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗